CAMBRIDGE, Mass.--(BUSINESS WIRE)--CAMP4 Therapeutics is on a mission to modernize the way the pharma industry discovers new treatments. Operating at the intersection of biology and computation, CAMP4 is building on seminal discoveries in gene regulation circuitry made by Company founders, Dr. Richard Young (Whitehead Institute/MIT) and Dr. Leonard Zon (Boston Children’s Hospital/Harvard University). Backing its ambitious plans, CAMP4 has brought together leading venture capital firms Polaris Partners, who initially seeded the Company, and Andreessen Horowitz, who led a $30 million Series A round, with continued participation from Polaris and The Kraft Group.
To enable its vision, CAMP4 is focusing efforts to scale its proprietary 4-D Gene Circuity Platform across all human cell types relevant to disease. “The machinery that controls activation of the 24,000 genes in the human body can be codified by CAMP4’s platform into a discrete set of combinatorial rules using signaling pathways. By combining novel experimental data and computational capabilities, our platform solves the control code for any gene and cell type central to disease pathology. We have already generated a high resolution 4-D map of the liver and all of its associated disease genes,” commented Josh Mandel-Brehm, Chief Executive at CAMP4.
CAMP4 believes the impact of its activities can substantially de-risk and shorten the drug development process, otherwise historically characterized by poor productivity and long approval timelines. Proceeds from the financing will be used to expand the use of its Platform to other human cell types and accelerate collaborations with partners toward novel target discoveries and new applications for existing chemistries, extending their life cycle and value into areas previously not considered.
“Since forming the company in 2016, we have seen the incredible impact of Camp4’s 4-D gene circuitry platform in generating insights into many currently unaddressed diseases. CAMP4’s technology has the potential to make a step change in both time and dollars required to discover new treatments for the sickest patients,” commented Amir Nashat, Partner at Polaris.
“By combining the power of epigenomics, computational biology and machine learning, CAMP4’s platform has the unique potential to elucidate the mechanisms and rules governing gene regulation across disease,” added Jorge Conde, General Partner at Andreessen Horowitz. “This is an extraordinary opportunity to transform how we think about discovering new therapies and treating patients.”
“We are extremely pleased to have brought together a syndicate of world-class investors from both biotech and tech fields. They share our commitment to deliver on the promise of our science and our vision to streamline drug discovery to bring more treatments to patients, faster,” concludes Mandel-Brehm.
Further information regarding CAMP4 can be found at https://www.camp4tx.com/.
About CAMP4 Therapeutics: Founded in 2016 and focused on a core mission of realizing a world with ‘an effective treatment option for every patient,’ CAMP4 Therapeutics evolved from seminal discoveries made by company founders Dr. Richard Young and Dr. Leonard Zon, characterizing the ways in which dynamic cell signaling networks control the expression of genes. Operating at the intersection of genomics, computational biology and data sciences, CAMP4 has extended this foundational work, creating a unique Gene Circuitry Platform to amplify the value of cellular and genetic insights to better understand how genes are controlled by signaling pathways in specific disease states. By generating proprietary 4D maps, CAMP4 can identify de-risked druggable targets, produce actionable insights and improve therapeutic predictability, potentially addressing hundreds of diseases and benefiting millions of patients globally. Find out more at www.camp4tx.com.